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Abstract.  We have found that the spontaneous migra- 
tion of bovine aortic endothelial cells from the edge of 
a  denuded area in a  confluent monolayer is dependent 
upon the release of endogenous basic fibroblast growth 
factor (bFGF).  Cell movement is blocked by purified 
polyclonal rabbit IgG to bFGF as well as affinity 
purified anti-bFGF IgG and anti-bFGF F(ab')2 frag- 
ments. The inhibitory effect of the immunoglobulins is 
dependent upon antibody concentration, is reversible, 
is overcome by the addition of recombinant bFGF, and 
is removed by affinity chromatography of the antise- 
rum through a column of bFGF-Sepharose.  Cell 
movement is also reversibly inhibited by the addition 
of protamine sulfate and suramin; two agents reported 
to block bFGF binding to its receptor.  The addition of 
recombinant bFGF to wounded monolayers accelerates 
the movement of cells into the denuded area.  Trans- 
forming growth factor I~ which has been shown to an- 
tagonize several other effects of bFGF also inhibits cell 
movement. The anti-bFGF IgG prevents the movement 
of bovine capillary endothelial cells, BHK-21,  NIH 
3T3, and human skin fibroblasts into a denuded area. 
Antibodies to bFGF, as well as suramin and protamine 
sulfate also suppress the basal levels of plasminogen 
activator and DNA synthesis in bovine aortic endo- 
thelial cells. 
B 
ASIC fibroblast  growth  factor  (bFGF) ~ is  a  potent 
mitogen for a number of cell types including fibro- 
blasts, endothelial cells, chondrocytes, adrenal corti- 
cal  cells,  and granulosa cells  (see  Gospodarowicz et al., 
1987  for review).  In  addition to  being  mitogenic, bFGF 
affects a variety of activities in cultured cells including pro- 
tease production (Moscatelli et al.,  1986b;  Presta et al., 
1986)  and chemotaxis (Moscatelli et al.,  1986b;  Presta et 
al., 1986), as well as supporting the maintenance and differ- 
entiation of neurons (Hatten et al.,  1988;  Morrison et al., 
1986; Walicke et al., 1986). bFGF is synthesized in vitro by 
a large number of cell types including fibroblasts (Moscatelli 
et al.,  1986a),  endothelial cells (Moscatelli et al.,  1986a; 
Vlodavsky et al., 1987a, b; Schweigerer et al., 1987b),  reti- 
nal pigment cells (Schweigerer et al., 1987a), granulosa cells 
(Neufeld et al., 1987), glial cells (Hatten et al., 1988), adre- 
nal cortical cells (Schweigerer et al., 1987c), and cells from 
a variety of tumor cell lines (Moscatelli et al., 1986a; Klags- 
brunet al.,  1986, Schweigerer et al.,  1987d). 
Since many cells that synthesize bFGF are capable of re- 
sponding  to  bFGF  through  interaction  with high affinity 
plasma membrane receptors, it is reasonable to hypothesize 
that bFGF acts as an autocrine factor in the regulation of 
specific  cellular  functions.  However,  the  nucleotide  se- 
1. Abbreviations used in this paper: BAE, bovine aortic endothelial; BCE, 
bovine capillary endothelial; bFGF, basic fibrob|ast growth factor; PA, plas- 
minogen  activator;  rbFGF,  recombinant basic  fibroblast growth  factor; 
qGFI3,  transforming growth factor IL 
quence of bFGF cDNA indicates that the protein is synthe- 
sized without a signal sequence (Abraham et al.,  1986a,  b; 
Kurokawa et al., 1987; Sommer et al., 1987) and, therefore, 
lacks the structural features normally required for protein 
secretion. Consistent with this is the observation that cells 
that synthesize bFGF appear to release little or no growth 
factor into the medium (Presta et al., 1986; Vlodavsky et al., 
1987b).  Thus, a growth factor that has the features of an au- 
tocrine hormone appears to be a cytoplasmic nonsecretory 
protein. 
In this study we report that the endogenous production of 
bFGF is required for the movement of bovine endothelial 
cells. Our results indicate that endothelial cell migration, as 
well as fibroblast migration, is regulated by bFGF released 
by the cells themselves. In addition, the basal level of synthe- 
sis of the protease plasminogen activator (PA) and the basal 
level of DNA synthesis in bovine aortic endothelial (BAE) 
ceils appear to be determined by the release of endogenous 
bFGF, as antibodies to bFGF suppress both of these activi- 
ties. These effects represent the first examples of natural au- 
tocrine roles of bFGE 
Materials and Methods 
Cell Culture 
BAE cells and bovine capillary endothelial (BCE) cells were isolated and 
grown as described previously (Gross et al.,  1982).  Briefly,  the cells were 
grown on gelatin-coated dishes in alpha minimal essential medium contain- 
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The Journal  of Cell Biology,  Volume 107, September 1988 1199-1205  1199 Figure 1.  BAE cell migration in the presence of anti-bFGF IgG.  Confluent monolayers of BAE cells were wounded with a  razor blade 
as described in Materials and Methods. The cells were incubated overnight in the indicated media, fixed, stained, and photographed. A, 
control; B, anti-bFGF IgG (200 I.tg/ml); C, nonimmune IgG (200 ~tg/ml). The arrows point to the original edge of the wound. Bar, 100 gm. 
ing 10% (BAE) or 5 % (BCE) calf serum. Cells were used between passages 
12-18. BHK-21 cells were the gift of Dr. C. Basilico (New York University 
Medical School). BHK-21, NIH 3T3, and human embryonic skin fibroblasts 
were grown in DME in 10% calf serum. 
bFGF 
Placental bFGF was prepared and assayed as described by Moscatelli  et al. 
(1986b), and Presta et al. (1986). Recombinant bFGF (rhFGF) was a gener- 
ous gift from Synergen,  Inc.  (Boulder,  CO). 
Anti-Human Placental bFGF Antibodies 
Polyclonal antibodies against human placental bFGF were raised in rabbits 
as described (Joseph-Silverstein  et al.,  1988).  These antibodies recognize 
human placental bFGF but no other heparin-binding proteins in a Western 
blot assay or in dot blot analysis.  DEAE Afli-Gel Blue (Bio-Rad Laborato- 
ries, Cambridge, MA) chromatography  was used to prepare IgG fractions 
according to the manufacturer's  instructions.  F(ab')2 fragments were pre- 
pared by pepsin digestion of purified IgG in acetate buffer at pH 4.5 (Stun- 
worth and Turner,  1978). The digestion was stopped by raising the pH to 
8.0. The F(alY)2 fragments were isolated  by gel filtration  through a 50-cm 
column of Sephadex  G  150 in Tris-HC1 buffer (pH 7.7). 
Wound Assays 
Confluent monolayers of endothelial cells were wounded with a razor blade 
as described by Burk (1973).  After wounding,  the cultures were  washed 
with PBS and further incubated in alpha minimal essential medium contain- 
ing 0.1% gelatin.  Control cultures,  antibody-treated  cultures,  and cultures 
containing suramin (Mobay Chemical Corp.,  Pittsburgh, PA), protamine 
sulfate (Sigma Chemical Co., St. Louis, MO), rbFGF, and/or transforming 
growth factor 13 (TGFIS) (R&D Systems,  Inc., Minneapolis, MN) were in- 
cubated at 37  ° for 16-20 h. After the incubation, the cells were fixed with 
absolute methanol and stained with Giemsa. Migration was quantitated  by 
counting the number of cells in successive  (7)  125-p,M sections  from the 
wound edge. Cells were counted at 100x magnification using a light micro- 
scope with an occular grid. The values represent the mean from four differ- 
ent fields. The percent inhibition was determined by dividing the number 
of cells that had moved from the wound edge in the experimental cultures 
by the number of cells that had moved from the wound edge in the control 
cultures,  multiplying this number by 100, and subtracting the product from 
100. 
Assays  for PA Induction 
Confluent cultures of BAE cells were incubated overnight under the various 
conditions indicated.  After incubation, the BAE cells were washed twice 
with PBS and extracted with 0.5% Triton X-100 in 0.1 M Tris-HC1, pH 8.1. 
The resulting  cell extracts  were assayed for PA activity  in the fibrin plate 
assay  (Gross et al.,  1982). 
Thymidine Incorporation Assay 
Confluent monolayers of BAE cells were maintained for 7 d in alpha mini- 
mal essential medium with 5% calf serum. The medium was then replaced 
with fresh alpha minimal essential  medium with 1% calf serum with or 
without 0.75 mM suramin. After 24-h incubation, the cultures were washed 
twice with PBS containing 0.75 mM suramin and incubated for a further 24 h 
in DME containing 0.5%  calf serum plus the additions  indicated.  During 
the second 24-h period,  the cells were  incubated  with [aH]thymidine  (1 
uCi/ml of [Methyl-3H]thymidine,  6.7 Ci/mMole; New  England Nuclear, 
Boston,  MA) and incorporation of [3H]thymidine into TCA precipitable 
material  after this period was determined by liquid scintillation  counting 
(Presta et al..  1986).  Under these conditions there is no increase  in cell 
number and thymidiue incorporation is <3 % of that observed in growing 
control cells. 
Results 
The migration of endothelial cells is one of the critical fea- 
tures of neovascularization and wound repair, two processes 
thought to involve bFGE  Therefore,  we examined the role 
of bFGF  in the movement of BAE cells from a  wound edge 
in vitro. The wound was made by removing a  patch of cells 
from a confluent monolayer with a  razor blade. To avoid the 
possible effects of serum factors,  all experiments were con- 
ducted  in  the  absence  of  serum.  Under  these  conditions, 
BAE cells rapidly moved from the edge of the wound into the 
open area (Fig.  1 A). The inclusion of anti-bFGF  IgG in the 
medium inhibited the migration of the cells into the denuded 
area (Fig.  1 B),  while the inclusion of nonimmune IgG had 
no effect on cell movement (Fig.  1 C).  Similar results were 
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Figure 2.  Quantitative dose-dependent inhibition of cell migration 
by anti-bFGF IgG. Confluent cultures of BAE cells were wounded 
as described  in Materials and Methods. The cells were incubated 
with the indicated additions for 20 h, fixed, and stained. Migration 
was quantitated by observing the cells with a grid marked in incre- 
ments of 125 ~tM. The number of cells within each 125-1aM area 
in four fields was counted using the original mark made by the razor 
blade as the origin. The results are presented as the average number 
of cells per field. A, control;  B, anti-bFGF IgG (25 txg/ml); C, 
anti-bFGF IgG (50  I.tg/ml); D, anti-bFGF IgG (100 Ixg/ml); E, 
anti-bFGF IgG (200 ~tg/ml). The total number of cells that moved 
from the edge of the wound was (A) 149, (B) 90, (C) 67, (D) 41, 
and (E) 20. 
obtained when this experiment was performed in the pres- 
ence  of serum  (data  not  shown).  Under  these  conditions 
round, refractile cells undergoing mitosis were present in the 
region of cell movement. Cells undergoing mitosis were not 
seen in the nonwounded regions. In the absence of serum no 
mitotic cells were apparent in the area of migration. 
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Figure 3. Potentiation of BAE cell migration by recombinant bFGF. 
6E 
Confluent monolayers of BAE cells were wounded as described in 
Materials  and Methods.  The cells were incubated overnight with  4a 
the indicated additions and migration was quantitated as described 
in the legend to Fig. 2. A, control; B, recombinant bFGF (1 ng/ml);  ~c 
C,  recombinant  bFGF  (10  ng/ml);  D,  recombinant  bFGF  (100  o 
ng/ml);  E, anti-bFGF IgG (200 ~tg/ml); F, anti-bFGF IgG (200 
Ixg/ml) plus recombinant bFGF (10 ng/ml); G, anti-bFGF IgG (200 
p.g/ml) plus recombinant bFGF (100 ng/ml).  The total number of 
cells that moved from the edge of the wound was (A) 78, (B) 139, 
(C)  164, (D)  125, (E) 32,  (F) 52,  and (G) 79. 
To quantitate  the  effect of the anti-bFGF antibodies  on 
BAE cell movement, cells were fixed and stained at the com- 
pletion of the experiment, and the distance moved measured 
in increments of 125 txm (Fig. 2). The antibody-induced in- 
hibition  of cell  movement occurred  in  a  dose-dependent 
manner with 40%  inhibition detected at an IgG concentra- 
tion of 25 I~g/ml (Fig. 2 B) and 87% inhibition at an IgG con- 
centration of 200  ~tg/ml (Fig.  2 D). 
Several control experiments were performed to verify the 
specificity of the antibody. Nonimmune IgG had no effect on 
cell movement nor did irrelevant antibodies  such as anti- 
fibronectin IgG or anti-BSA IgG (data not shown). The addi- 
tion of rbFGF potentiated BAE cell movement (Fig. 3, B, C, 
and D) from 60 to 110% depending upon the dose. The addi- 
tion of rbFGF to medium containing anti-bFGF IgG reversed 
the inhibitory effect of the immune IgG (Fig.  3, F  and G). 
Chromatography of the anti-bFGF IgG preparation through 
a column of rbFGF-Sepharose removed the inhibitory activ- 
ity (Fig. 4, D and E). Moreover, the antibodies eluted from 
the rbFGF-Sepharose column retained their inhibitory activ- 
ity at a significantly lower concentration (Fig. 4 F). These 
experiments indicated that the inhibition of BAE migration 
was a  direct consequence of the neutralization of bFGF by 
the antiserum. 
Suramin, a polyanionic trypanocidal drug, and protamine 
sulfate, a small basic protein, have been reported to block the 
interaction  of bFGF  with  its  receptor  (Coffey, Jr.,  et al., 
1987; Neufeld and Gospodarowicz,  1987).  Both suramin and 
protamine sulfate also inhibited BAE cell movement (Table 
I). The effects of both compounds were reversible (Table I). 
Heparin, another molecule that interacts with bFGF but does 
not affect bFGF binding to its receptor (Moscatelli,  1987), 
neither stimulated nor inhibited cell movement (Table I). 
Previous experiments by Frater-Schroeder  et al.  (1986) 
and Baird and Durkin (1986), demonstrated that TGF~ can 
block the mitogenic effect of bFGF, and Saksela et al. (1987) 
have shown that  TGFI3  suppresses the induction  of PA  in 
BCE cells by bFGE  Therefore, we monitored the effect of 
TGFI~ on BCE movement (Table I). TGFI~ at a concentration 
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Figure  4.  Effect  of  affinity 
purified  anti-bFGF  antibod- 
ies.  Confluent  monolayers of 
BAE  cells  were  wounded  as 
described  in  Materials  and 
Methods. The cells were incu- 
bated overnight with the indi- 
cated additions and migration 
was quantitated  as described 
in the legend to Fig. 2. A, con- 
trol; B, nonimmune IgG (200 
~tg/ml); C,  nonimmune  IgG 
after passage  through  a  col- 
umn of bFGF-Sepharose (200 
ktg/ml);  D,  anti-bFGF  IgG 
(200  lag/ml); E,  anti-bFGF 
IgG after passage  through  a 
column  of  bFGF-Sepharose 
(200 t.tg/ml); F, lgG bound to 
bFGF-Sepharose and eluted with 0.1 M glycine, pH 2.5 (2 lag/ml). 
The total number of ceils that moved from the edge of the wound 
was (A) 118, (B)  154, (C)  151, (D) 41, (E)  128, and (F) 48. 
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BAE Cell Migration 
Migration 
Addition  (percent of control) 
Nonimmune  IgG (200 I.tg/ml) 
Immune  IgG (200 ~tg/ml) 
Suramin  (0.5 mM) 
Suramin  (0.5 mM) removed  after 20 h 
Protamine  (0.5 ~g/ml) 
Protamine (0.5 p.g/ml) removed after 20 h 
Heparin (10  p.g/ml) 
TGF[3 (2 ng/ml) 
rbFGF (20 ng/ml) 
TGFI~ (2 ng/ml) plus rbFGF (20 ng/ml) 
100 
98 
27 
4 
110 
11 
84 
97 
49 
170 
111 
Confluent monolayers  of BAE cells were wounded as described in Materials 
and Methods. The cells were incubated  for 20 h in media  containing  the listed 
additions, fixed,  and cell migration  was quantitated. In the case of suramin and 
protamine, after a 20-h incubation,  the drugs were removed from the cultures 
by washing, the medium  was replaced  with  control medium, and the cells were 
fixed  and counted  after a further 20-h incubation.  In the control  cultures, 100% 
represents a total of 118 cells that had moved from the edge of the wound or 
in the case of the TGFI~ and rbFGF experiments, 176 cells. 
of 2  ng/ml inhibited BAE cell movement by 51%  (Table I). 
This  result  confirms  an  earlier report  of Heimark  et  al. 
(1986)  describing the  inhibition of BAE cell migration by 
TGFI3.  The  inhibitory effect of TGFI~ was  reversed by the 
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Figure 5.  Effect  of suramin  incubation on  BAE cell migration. 
Confluent cultures of BAE cells were incubated for 2 h with 0.5 mM 
suramin, wounded as described in Materials and Methods, washed 
twice with PBS containing 0.5 mM suramin and incubated over- 
night with the indicated additions. Cell migration was quantitated 
as described in the legend to Fig. 2. A, control; B, suramin removed 
after the PBS wash; C, suramin present throughout; D, suramin re- 
moved after an overnight incubation, and the culture incubated in 
control medium for an additional 20 h; E, suramin removed after 
overnight incubation, replaced by nonimmune IgG (200  lag/ml), 
and the culture incubated for an additional 20 h; F, suramin re- 
moved after overnight incubation, replaced by anti-bFGF lgG (200 
lxg/ml), and the culture incubated for an additional 20 h. The total 
number of cells that moved from the edge of the wound was (A) 102, 
(B) 80, (C) 6, (D)  126, (E)  141, and (F)  19. 
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Figure 6.  Removal  of bFGF  from 
high and low affinity sites by sura- 
min. Confluent cultures of BAE cells 
were  incubated  with  2.5  ng/ml  of 
125I-bFGF (542 cpm/fmoi) for 2 h at 
4°C.  The  cultures  were  quickly 
washed twice with ice-cold PBS and 
incubated with either control medi- 
um  or medium containing suramin 
(0.5 mM) for 2 h at 4°C. At the end 
of 2 h the medium was removed and 
~25I counted.  The  radioactivity re- 
maining with the cell layer was ana- 
lyzed for t25I-bFGF binding to both high and low affinity sites as 
described by Moscatelli (1987).  Column 1, radioactivity remaining 
associated with cells in control cultures; column 2, radioactivity in 
the medium after a 2-h incubation of control cultures; column 3, 
radioactivity associated with cells after a 2-h incubation with sura- 
min (0.5 raM); column 4, radioactivity in the medium after a 2-h 
incubation with suramin (0.5 mM). t:3, high affinity binding; ¢¢~, 
low affinity binding; ~,  radioactivity in culture fluid. 
simultaneous  addition of sufficient rbFGF with the TGFI3 
(Table I). 
These results indicate that the release of bFGF is required 
for the movement of BAE cells from a wound edge. As bFGF 
lacks a signal sequence, the mechanism for its release from 
cells is unclear. It is possible that the bFGF responsible for 
BAE migration was liberated only from BAE cells injured 
during wounding.  Conversely, bFGF may be continuously 
released by BAE cells under the culture conditions. We at- 
tempted to distinguish between these two alternatives by the 
following experiment. BAE monolayers were wounded in the 
presence of 0.5 mM suramin to prevent any bFGF released 
from binding to the cells (Fig. 5).  After wounding, the cul- 
tures were washed twice with PBS containing suramin to re- 
move released bFGF and incubated for 20 h in the presence 
(Fig. 5 C) or absence (Fig. 5 B) of suramin. When suramin 
was present continuously, there was no significant cell move- 
ment from the wound edge (compare Fig. 5 A with C). How- 
ever,  when suramin was present only during the wounding 
and PBS wash, and subsequently removed, only a slight inhi- 
bition (20%) of cell movement was detected (Fig. 5 B). The 
effect of continous exposure to suramin was reversible. If the 
suramin was removed after a 20-h exposure, cell migration 
resumed during a  subsequent 20-h period (Fig.  5 D).  The 
resumption of cell movement was unaffected by the inclusion 
of nonimmune IgG (Fig. 5 E) but was inhibited by immune 
IgG (Fig.  5 F). 
While it is possible that some bFGF released by the act of 
wounding may have remained bound to the matrix, this is un- 
likely since suramin removes bFGF bound to the matrix low 
affinity binding sites as well as blocking bFGF from binding 
to  its  high  affinity plasma  membrane  receptor.  This  was 
shown  by  exposing BAE  cultures to  t25I-bFGF for 2  h  at 
4°C to permit binding to both high and low affinity binding 
sites (Fig.  6,  column  l;  Moscatelli,  1987).  The cells were 
then  incubated for 2  h  in bFGF-free medium.  During this 
time,  ~36%  of the  cell-associated radioactivity reequili- 
brated into the culture medium (Fig. 6,  column 2).  Of the 
tzsI-bFGF that  remained cell associated,  *7%  was  bound 
to  high  affinity  receptors,  while  93%  was  bound  to  low 
affinity binding sites probably representing heparan sulfate 
The Journal of Cell Biology, Volume 107, 1988  1202 Table II.  Effect of Anti-bFGF lgG on the Migration  of 
Other Cell Types 
Migration 
Cell type  Addition  (percent of control) 
BHK-21  -  100 
BHK-21  50 l.tg/ml IgG  0 
BCE  -  lOO 
BCE  200 I.tg/ml IgG  6 
NIH 3T3  -  100 
NIH 3T3  200 p.g/ml IgG  25 
HES  -  100 
HES  200 ~tg/ml IgG  22 
Confluent monolayers of cells were wounded as described in Materials and 
Methods. Increasing  amounts of  anti-bFGF lgG were added to the experimental 
cultures, the cells were incubated overnight, the monolayers  were fixed, and 
the number  of  cells that had migrated from  the edge  of  the wound  were counted. 
The results for the maximum  amount  of IgG used are presented as a percentage 
of the control. The number of cells that migrated in the control cultures were 
64 for BHK-21, 114 for BCE cells, 20 for NIH 3T3, and 36 for human em- 
bryonic skin (HES). 
molecules  (Fig.  6,  column  1).  If cells  preincubated  with 
t2SI-bFGF  were  subsequently  incubated  with  bFGF-free 
medium containing 0.5 mM suramin for 2 h, the amount of 
125I-bFGF  that  remained  associated  with  the  cells  was  re- 
duced to 4 % of the total initially bound (Fig. 6, columns 3 
and 4).  This was evenly distributed  between high and low 
affinity binding sites.  Thus, a 2-h exposure to suramin dis- 
sociated >76 % of the bFGF bound to high affinity sites and 
98 %  bound to low affinity sites.  These results  suggest that 
suramin can not only block bFGF-receptor binding but also 
can remove bFGF already bound to cell receptors and ma- 
trix.  Therefore,  after  an overnight incubation  in  suramin- 
containing medium (Fig. 5 D), very little bFGF would have 
remained complexed to cells or their matrices,  and the re- 
sumption of cell movement after removal of the suramin must 
have been due to the continuous release of bFGF by the cells. 
The bFGF-dependence of cell migration was not unique to 
BAE cells. BCE, NIH 3T3, BHK-21, and human embryonic 
skin fibroblast cell movement were all blocked by anti-bFGF 
IgG (Table II). With the exception of BCE cells, the number 
of cells that migrated was significantly lower than that ob- 
served with BAE cells. The inhibition of BHK-21 cell move- 
ment by antibodies to bFGF was surprising since these cells 
have been reported not to produce bFGE An examination of 
the BHK-21 ceils revealed,  however, that the strain used in 
our study did contain low levels of bFGF (Sato, Y., and M. 
Renko,  unpublished  observation).  Consistent  with  this ob- 
servation, the concentration of antibody required for inhibi- 
tion of BHK-21 cell movement was significantly less than that 
required  for the  inhibition  of BAE cells  that contain  rela- 
tively high amounts of bFGF. 
Since bFGF stimulates the synthesis of PA by endothelial 
cells (Moscatelli et al.,  1986b; Presta et al.,  1986; Saksela 
et al., 1987), we next examined the role of endogenous bFGF 
in regulating basal PA levels. Cultures of BAE cells were in- 
cubated  in serum-free  medium either with no additions or 
with immune or nonimmune rabbit IgG. As can be seen from 
Fig. 7, exposure of the cells to immune IgG suppressed the 
level of PA activity by 85 %,  while the inclusion of nonim- 
mune IgG had little  effect.  Suramin  and protamine  sulfate 
also caused a decrease in PA levels (data not shown). The ob- 
o  R 
1  2  3 
Figure  7. Inhibition of plasminogen acti- 
vator production by anti-bFGF IgG. Cul- 
tures  of confluent  BAE  cells  were  in- 
cubated  with  the  indicated  additions 
overnight,  and the PA level  of the cells 
were measured in cell extracts.  Column 1, 
control cultures;  column 2,  nonimmune 
IgG (200  ~tg/ml); column 3,  anti-bFGF 
IgG (200 ~tg/ml). 
served decrease in PA activity represented an actual diminu- 
tion in the amount of PA present as monitored by analysis of 
PA  levels  after  SDS-PAGE  and  zymography  (data  not 
shown).  In addition,  no substantial  increase  in the amount 
of PAl-l, an inhibitor of PA synthesized by endothelial cells 
(van Mourik et al.,  1984), was observed under these condi- 
tions (data not shown). Similar results on the suppression of 
basal PA production by anti-bFGF IgG have been obtained 
with BCE cells. Thus, in addition to cell migration, the basal 
level of PA synthesis in bovine endothelial ceils may be regu- 
lated by the release of endogenous bFGE 
A similar experiment was performed to monitor the effect 
of anti-bFGF IgG on DNA synthesis by confluent BAE cells 
maintained in low serum. Under the conditions described in 
Materials and Methods, the basal level of [3H]thymidine in- 
corporation was not suppressed when anti-bFGF  IgG was 
added to cultures of confluent BAE cells in 0.5 % serum-con- 
taining medium  (data not shown).  This result  is similar to 
that reported earlier by Schweigerer et al. (1987b) using BCE 
cells  and  an  antiserum  to  bFGF.  Since  suramin  removes 
bFGF from matrix and can be applied to the cultures in rela- 
tively  high  amounts,  we  treated  confluent  serum-starved 
BAE ceils with 0.75  mM suramin to displace bound bFGF 
and  measured  [3H]thymidine  incorporation  (Fig.  8,  col- 
umns 1 and 3). This treatment decreased DNA synthesis by 
'~86%. The effect was reversible as removal of suramin after 
a 24-h exposure to the drug resulted in a recovery of DNA 
synthesis  during  a  subsequent  24-h  incubation  (Fig.  8, 
column 2). If, after 24 h of exposure, suramin was removed 
and replaced with anti-bFGF IgG, there was no recovery of 
[3H]thymidine incorporation (Fig.  8, column 5).  If nonim- 
A 
×  1 
o iI. 
1  2  3  4  5 
Figure 8.  Suppression of DNA synthesis 
by anti-bFGF IgG. Confluent  cultures  of 
BAE cells were treated with the various 
regimens  described below and incubated 
in  medium  containing  [3H]thymidine  (1 
uCi/ml)  for 24 h.  After incubation,  the 
cells were washed,  and [3H]thymidine in- 
corporation into  TCA-insoluble  material 
was measured as  described in Materials 
and  Methods.  Column  1,  control  cells; 
column 2, suramin (0.75 mM)incubation 
overnight followed by removal of suramin and a 24-h incubation  in 
control medium; column 3,  incubation  with suramin  throughout; 
column 4, incubation with suramin overnight followed by a 24-h in- 
cubation with nonimmune IgG (200 ~tg/ml); column 5, incubation 
with suramin  overnight followed by a 24-h incubation  with anti- 
bFGF IgG (200 I.tg/ml). 
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50% above that of the control (Fig. 8, column 4). This in- 
crease in DNA synthesis to levels above the control may be 
the result of contaminating growth factors in the IgG prepa- 
ration. The effect of the suramin anti-bFGF IgG treatment 
on BAE cells was similar for both confluent and sparse cul- 
tures (data not shown).  These results demonstrate that the 
basal  level  of DNA  synthesis  in  BAE  confluent  serum- 
starved cultures can be regulated by the release of endoge- 
nous bFGF. 
Discussion 
The results presented here demonstrate that the release of 
bFGF by BAE cells affects their movement and their basal 
levels  of  PA  and  DNA  synthesis.  We  have  previously 
reported that the release of bFGF from glial cells is impor- 
tant for the maintenance of cultured neurons (Hatten et al., 
1988). In those experiments, bFGF release by glial cells in 
cocultures of glia and  neurons was  required for both the 
maintenance and differentiation of the neurons.  Those ex- 
periments demonstrated that bFGF can function as a para- 
crine hormone. In the experiments described in this paper, 
endothelial cell functions were stimulated by endogenous 
bFGF demonstrating that bFGF can also act as an autocrine 
factor. 
While our experiments appear to be the first documented 
example of an autocrine activity of bFGE at least one earlier 
report described effects that may represent the autocrine ac- 
tivity of bFGE Gospodarowicz et al. (1976) described an ex- 
periment in which endothelial cells seeded at low density did 
not survive in the absence of serum unless supplemented 
with crude FGE while endothelial cells at high density sur- 
vived in the absence of added serum or growth factor. At the 
time this experiment was performed, it was not appreciated 
that endothelial cells synthesize high levels of bFGE In ret- 
rospect these results can be interpreted as evidence for auto- 
crine conditioning of the culture medium with bFGF at high 
cell density, with insufficient amounts of  bFGF accumulating 
at low cell density. 
Baird et al. (1988) have recently shown that certain bFGF 
peptides may act as antagonists for the basal cell growth of 
BAE ceils. These results are consistent with our observations 
on the role of endogenous bFGF on the BAE phenotype. 
After this work was completed, two papers appeared indi- 
cating that when cells were transfected with high expression 
plasmids for bFGF, changes in the cell phenotype could be 
observed (Sasada et al.,  1988; Rogelj et al.,  1988). In one 
case the observed morphological change was  slightly  re- 
verted upon the inclusion of anti-bFGF antibodies (Sasada 
et al.,  1988). Therefore, over-expression of bFGF may also 
have profound effects on cells. 
The migratory nature of cells at the edge of a  wounded 
monolayer was observed over 18 years ago. The nature of the 
stimulus for this response has been explored since that time 
and a number of explanations of this phenomenon have been 
put forth, including alterations in the matrix (Stoker and Pig- 
gott,  1974),  the activity of specific cell migration factors 
(Burk,  1973), and the action of plasmin (Ossowski et al., 
1973,  1975).  Since bFGF is believed to initiate endothelial 
cell migration during neovascularization and wound healing, 
we examined the role of bFGF in cell migration in vitro. 
While the chemotactic activity of bFGF has been described 
(Moscatelli et al.,  1986b; Presta et al.,  1986), the observed 
requirement for the release of endogenous bFGF for cell 
migration was unexpected. 
These  results,  however,  confirm  a  number  of earlier 
reports and provide an interpretation for certain unexplained 
observations. For example, Heimark et al. (1986) described 
the inhibitory effect of TGFI3 on movement and mitosis in 
wounded monolayers of BAE cells. Their observations, as 
well as the observations of a number of groups that TGFI~ 
blocks the action of bFGF (Baird and Durkin, 1986; Frater- 
Schroder et al.,  1986; Saksela et al.,  1987), are consistent 
with a requirement for endogenous bFGF for cell movement. 
In the experiments of Heimark et al. (1986), the inhibitory 
effect of TGFI~ was lost after 24 h. This is in agreement with 
the finding of Saksela et al. (1987) that the suppressive effect 
of  TGFI5 on bFGF-induced endothelial cell PA synthesis lasts 
for only 24 h. Thus, in the experiments of Heimark et al., 
the  initial  TGFIS-induced  inhibition of cell migration was 
probably neutralized after 24 h by the stimulatory effect of 
bFGF released by the endothelial cells. 
bFGF stimulates the synthesis of  PA in BAE cells. A possi- 
ble involvement of PA in the migratory process is consistent 
with a number of other observations. Earlier work by Os- 
sowski  et al.  (1973,  1975) demonstrated that plasmin con- 
tributed to cell migration. Morioka et al. (1987) reported that 
in keratinocyte monolayers wounding is followed by the ex- 
pression of PA,  and presumably the formation of plasmin, 
by cells at the edge of the wound.  Recently Pepper et al. 
(1987)  demonstrated  a  similar  stimulation  of  urokinase 
production at the edge of a wound in BAE cultures. There- 
fore, it will be of interest to determine if antibodies to bFGF 
prevent the induction of PA synthesis at the edge of a wound 
and if this blocks migration. However, an alternative expla- 
nation is that bFGF acts as a motility factor via its adhesive 
interactions described by Baird et al.  (1988). 
Perhaps, the most intriguing question raised by these ex- 
periments is the mechanism by which bFGF reaches the ex- 
tracellular space, bFGF has no signal sequence and normally 
appears to be released from cells in limited amounts. It has 
been suggested that bFGF release occurs after cell death or 
damage. While this may be true, it is difficult to prove under 
normal culture conditions. Given the level of bFGF in BAE 
cells, ,025,000 molecules per cell, and the number of high 
affinity receptors per BAE cell, 3,000 (D.  Moscatelli, per- 
sonal communication), the death of  a few cells would release 
sufficient growth factor to yield a response. While wounding 
may have caused the release of bFGF due to cell death, the 
reversible effects of suramin in wounding experiments, cou- 
pled with the ability of anti-bFGF IgG to modulate the syn- 
thesis of PA and DNA under conditions of minimal perturba- 
tion of the cells, strongly suggest that bFGF is continuously 
released in BAE cultures. The mechanism of bFGF release 
from BAE cells and the control of its extracellular activity 
are currently being explored. 
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